Dapagliflozin
Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine[1]. Dapagliflozin induces HIF1 expression and attenuates renal IR injury[2].
Product Specifications
CAS Number
461432-26-8
Product Name Alternative
BMS-512148
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
SGLT
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/Dapagliflozin.html
Purity
99.97
Solubility
DMSO : 140 mg/mL (ultrasonic)
Smiles
O[C@H]1[C@H](C2=CC(CC3=CC=C(OCC)C=C3)=C(Cl)C=C2)O[C@H](CO)[C@@H](O)[C@@H]1O
Molecular Formula
C21H25ClO6
Molecular Weight
408.87
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
SGLT2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD50 (ICAM-3) (101-1D2), CF405S conjugate, 0.1mg/mL
ACTH (Adrenocorticotrophic Hormone) (AH26), CF647 conjugate, 0.1mg/mL
MART-1 / Melan-A (M2-7C10), CF594 conjugate, 0.1mg/mL
Calponin-1 (CNN1/832), CF647 conjugate, 0.1mg/mL
